Cargando…

Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report

Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenxin, Ma, Zuohong, Fu, Xibo, Hao, Zhiqiang, Shang, Hai, Shi, Junping, Lei, Mengping, Xu, Mian, Ning, Shili, Hua, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506765/
https://www.ncbi.nlm.nih.gov/pubmed/34734039
http://dx.doi.org/10.21037/atm-21-3681
_version_ 1784581755666169856
author Li, Wenxin
Ma, Zuohong
Fu, Xibo
Hao, Zhiqiang
Shang, Hai
Shi, Junping
Lei, Mengping
Xu, Mian
Ning, Shili
Hua, Xiangdong
author_facet Li, Wenxin
Ma, Zuohong
Fu, Xibo
Hao, Zhiqiang
Shang, Hai
Shi, Junping
Lei, Mengping
Xu, Mian
Ning, Shili
Hua, Xiangdong
author_sort Li, Wenxin
collection PubMed
description Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a breast cancer 2 (BRCA2)-inactivating rearrangement mutation that had an obvious reaction to olaparib therapy. The patient was a 68-year-old man with postoperative recurrence of extrahepatic CCA (ECC) who declined systemic chemotherapy. In August 2015, abdominal computed tomography (CT) of the patient revealed intrahepatic bile duct dilatation, obstruction at the hepatic hilar region proximal to the common hepatic duct, and splenomegaly, and radical surgical resection was performed. Postoperative histopathology diagnosis was ECC without metastases. In February 2017, abdominal CT revealed local recurrence, and the patient refused chemotherapy. BRCA2 rearrangement were detected by next-generation sequencing. Oral administration of olaparib was initiated. The patient achieved stable disease 1 month later, progression-free survival for >10 months without any significant adverse reactions, and an overall survival (OS) of 27 months. This is the first report demonstrating the clinical benefits of olaparib in a BRCA2 rearrangement-harboring patient with ECC. This observation would help determine the best treatment option for advanced ECC patients.
format Online
Article
Text
id pubmed-8506765
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85067652021-11-02 Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report Li, Wenxin Ma, Zuohong Fu, Xibo Hao, Zhiqiang Shang, Hai Shi, Junping Lei, Mengping Xu, Mian Ning, Shili Hua, Xiangdong Ann Transl Med Case Report Cholangiocarcinoma (CCA) is a malignant tumor with poor prognosis and high recurrence rate. There is no standard treatment for advanced CCA beyond first-line chemotherapy, which provides only limited benefits. In this study, we report a case of a postoperative recurrence ECC patient harboring a breast cancer 2 (BRCA2)-inactivating rearrangement mutation that had an obvious reaction to olaparib therapy. The patient was a 68-year-old man with postoperative recurrence of extrahepatic CCA (ECC) who declined systemic chemotherapy. In August 2015, abdominal computed tomography (CT) of the patient revealed intrahepatic bile duct dilatation, obstruction at the hepatic hilar region proximal to the common hepatic duct, and splenomegaly, and radical surgical resection was performed. Postoperative histopathology diagnosis was ECC without metastases. In February 2017, abdominal CT revealed local recurrence, and the patient refused chemotherapy. BRCA2 rearrangement were detected by next-generation sequencing. Oral administration of olaparib was initiated. The patient achieved stable disease 1 month later, progression-free survival for >10 months without any significant adverse reactions, and an overall survival (OS) of 27 months. This is the first report demonstrating the clinical benefits of olaparib in a BRCA2 rearrangement-harboring patient with ECC. This observation would help determine the best treatment option for advanced ECC patients. AME Publishing Company 2021-09 /pmc/articles/PMC8506765/ /pubmed/34734039 http://dx.doi.org/10.21037/atm-21-3681 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Case Report
Li, Wenxin
Ma, Zuohong
Fu, Xibo
Hao, Zhiqiang
Shang, Hai
Shi, Junping
Lei, Mengping
Xu, Mian
Ning, Shili
Hua, Xiangdong
Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title_full Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title_fullStr Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title_full_unstemmed Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title_short Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
title_sort olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a brca2-inactivating mutation: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506765/
https://www.ncbi.nlm.nih.gov/pubmed/34734039
http://dx.doi.org/10.21037/atm-21-3681
work_keys_str_mv AT liwenxin olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT mazuohong olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT fuxibo olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT haozhiqiang olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT shanghai olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT shijunping olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT leimengping olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT xumian olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT ningshili olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport
AT huaxiangdong olaparibeffectivelytreatslocalrecurrenceofextrahepaticcholangiocarcinomainapatientharboringabrca2inactivatingmutationacasereport